Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Feb. 28, 2023 shares	Nov. 01, 2022	Sep. 30, 2022 $ / shares
Summary of Significant Accounting Policies (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Common stock convertible exchange ratio	2.0719			2.0719
Restricted bank account collateral for credit card	$ 60,000	$ 60,000
Restricted cash collateral for secured letter of credit		177,000
Federal depository insurance coverage	250,000
Impairment loss on operating right-of-use asset	$ 3,513,999	$ 0
Common stock, shares outstanding | shares	23,124,888	19,782,747
Stock options | shares	1,698,754	1,750,967	335,646
Conversion price per share | $ / shares					$ 10
US Army Medica Research Acquisition Activity [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Grant revenue	$ 400,000	$ 600,000
Grant revenue | US Army Medica Research Acquisition Activity [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Grant revenue	$ 400,000	$ 600,000
pH Pharma, Inc. [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Ownership percentage in subsidiary	100.00%